BusinessTESARO Summarizes ZEJULA and TSR-042 Data Presented at the 2017 ESMO Annual MeetingBy Nasdaq OMXSep 11, 2017, 12:01 PM UTC
BusinessTESARO Announces Nine Data Presentations at the 2017 European Society for Medical Oncology (ESMO) Annual MeetingBy Nasdaq OMXAug 25, 2017, 12:01 PM UTC
Business2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121By Nasdaq OMXAug 9, 2017, 2:30 PM UTC
BusinessTESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in JapanBy Nasdaq OMXJul 27, 2017, 11:01 AM UTC
BusinessOncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 / 2X-121By Nasdaq OMXJul 7, 2017, 12:30 PM UTC
BusinessTesaro Announces Priority Review Designation for Niraparib NDABy Nasdaq OMXDec 20, 2016, 1:00 PM UTC
BusinessTesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian CancerBy Nasdaq OMXNov 1, 2016, 8:30 PM UTC
BusinessTESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016By Nasdaq OMXOct 8, 2016, 6:15 AM UTC
